Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-243 in healthy adults and healthy Asian adults
NCT07306754Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-243 in ulcerative colitis (UC) and Crohn's disease, sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at Day 204, Maximum Observed Serum Concentration of ABBV-243 at Day 204 and 5 more. Started Dec 2025; status: recruiting.
02
Drugs
ABBV-243
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT07306754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306754.